Bengaluru, Karnataka, India – March 28, 2023
Biocon Biologics Ltd (BBL), a subsidiary of Biocon Ltd, today announced that it has won the prestigious ‘Bioprocessing Excellence in South Asia’ Award at the Asia-Pacific Bioprocessing Excellence Awards (ABEA) 2023 held in Singapore earlier this month.
Biocon Biologics is a frontrunner in the global biosimilars industry and is committed to scientific innovation, the highest standards of quality compliance and global scale manufacturing capabilities to serve patients and healthcare systems across the globe.
Commenting on the development, Kiran Kumar Gandhirajan, Site Head, Biocon Malaysia, said, “We are delighted and proud to receive the ‘Bioprocessing Excellence in South Asia’ Award. It is a recognition of our longstanding expertise in process sciences, state-of-the-art manufacturing capabilities, operational excellence and high standards of quality compliance. These strengths have enabled us to expand patient access to high quality affordable biosimilars and make a meaningful difference to global healthcare.”
Biocon Biologics was recognized as the winner as it garnered the maximum number of votes from among 70,000 biopharma professionals who participated in the survey. The annual Asia-Pacific Bioprocessing Excellence Awards organized by IMAPAC, recognize organizations who demonstrate exceptional bioprocessing expertise and the use of best-in-class technologies and practices to achieve biomanufacturing excellence in terms of speed, reduced cost, and superior quality.
Biocon Biologics has developed multiple technology platforms that use various expression systems such as bacteria, yeast, and mammalian cells.
The Pichia Pastoris platform technology used to express recombinant proteins is a proprietary technology developed by Biocon and used for its recombinant human insulin and insulin analog products. Similarly, the company’s scalable mammalian CHO and NSO cell-based expression platforms and robust process science expertise allow it to develop and manufacture both novel and biosimilar monoclonal antibodies for global markets.
Each year, IMAPAC — the organizing committee of ABEA 2023 — calls for nominations from the IMAPAC biologics community for different biologics award categories. All entries and nominations are considered and submitted to the judging panel and market research team from IMAPAC. Based on the number of nominations and assessment, the top 5-7 entries under each category are shortlisted. From among the top 5-7 entries, the ABEA winners are determined through voting by the public or bioprocessing community.
About Biocon Biologics
Biocon Biologics Ltd. (BBL), a subsidiary of Biocon Ltd., is a unique, fully integrated, global biosimilars company committed to transforming healthcare and transforming lives by enabling affordable access to affordable biologics for millions of patients worldwide. It is leveraging cutting-edge science, innovative tech platforms, global scale manufacturing capabilities and world class quality systems to lower costs of biological therapeutics while improving healthcare outcomes. BBL has acquired the global biosimilars business of its long-standing partner Viatris, which is a historic milestone in its value creation journey. Biocon Biologics has commercialized eight biosimilars in key emerging markets and advanced markets like U.S., EU, Australia, Canada, Japan. The Company has a pipeline of 20 biosimilar assets across diabetology, oncology, immunology, and other non-communicable diseases. It has many ‘firsts’ to its credit in the biosimilars industry. It has also signed a strategic alliance with Serum Institute Life Sciences for vaccines (subject to certain closing conditions) to address the inequitable access to lifesaving vaccines. As part of its environmental, social and governance (ESG) commitment, BBL is advancing the health of patients, people and the planet to achieve key UN Sustainable Development Goals (SDGs). Website: www.bioconbiologics.com; Follow us on Twitter: @BioconBiologics for company updates.
Biocon Limited, publicly listed in 2004, (BSE code: 532523, NSE Id: BIOCON, ISIN Id: INE376G01013) is an innovation-led global biopharmaceuticals company committed to enhance affordable access to complex therapies for chronic conditions like diabetes, cancer and autoimmune. It has developed and commercialized novel biologics, biosimilars, and complex small molecule APIs in India and several key global markets as well as Generic Formulations in the US and Europe. It also has a pipeline of promising novel assets in immunotherapy under development. Website: www.biocon.com; Follow-us on Twitter: @bioconlimited for company updates.